Enantioselective Analysis of Amphetamine-Related Designer Drugs in Body Fluids Using Liquid Chromatography and Solid-Phase Derivatization

Abstract

A method for the enantioselective determination of the amphetamine-derived designer drugs 3,4-methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxyethylamphetamine (MDE) based on their derivatization with (-)-1-(9-fluorenyl)ethyl chloroformate (FLEC) is described. The proposed procedure entails preconcentration and derivatization of the analytes into C₁₈-packed solid-phase extraction cartridges, chromatographic separation of the diastereomers originated in a C₁₈ column under gradient elution, and UV detection at 265 nm. Compared with the solution derivatization approach the described procedure increased analyte responses by factors of 28–58. The reliability of the method has been tested by analysing plasma and urine samples spiked with the analytes in the 0.015–1.0 μg mL⁻¹ concentration interval. The proposed conditions provided adequate linearity, and coefficients of variation ranging from 5% to 14% in plasma, and from 3% to 12% in urine. The recoveries of the analytes were of 78%–126% and 78%–128% in plasma and urine, respectively. The limits of detection (LODs) obtained for all the analytes were 5 ng mL⁻¹ in both biological matrices.